JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Scope & Guideline
Empowering Clinicians with Groundbreaking Findings
Introduction
Aims and Scopes
- Thrombosis and Hemostasis Mechanisms:
Investigates the fundamental biological processes underlying thrombosis and hemostasis, including coagulation pathways, platelet function, and the role of the endothelium. - Bleeding Disorders:
Focuses on the diagnosis, treatment, and management of inherited and acquired bleeding disorders, such as hemophilia, von Willebrand disease, and others. - Anticoagulation and Thrombotic Risk Management:
Explores the efficacy and safety of anticoagulant therapies, risk assessment strategies, and guidelines for managing patients at risk of thromboembolic events. - Clinical Trials and Innovations:
Reports on novel therapeutic approaches, including gene therapies, monoclonal antibodies, and emerging anticoagulants, aimed at improving patient outcomes. - Translational Research:
Emphasizes studies that translate laboratory findings into clinical practice, providing insights that can directly impact patient care in thrombosis and hemostasis. - Guidelines and Best Practices:
Provides updates and consensus guidelines from leading experts and committees on the management of various thrombotic and bleeding disorders.
Trending and Emerging
- Gene Therapy for Hemophilia:
Emerging studies on gene therapy approaches for hemophilia treatment are on the rise, showcasing innovative strategies to address genetic deficiencies in coagulation factors. - COVID-19 Related Thrombosis Research:
Significant attention is being given to the thrombotic complications associated with COVID-19, including mechanisms, management, and long-term outcomes. - Personalized Medicine in Thrombosis Management:
Research focusing on individualized treatment strategies, including the use of genetic and phenotypic markers to guide anticoagulation therapy, is gaining traction. - Impact of Inflammation on Coagulation:
Studies exploring the relationship between inflammation and coagulation pathways are becoming increasingly relevant, particularly in chronic diseases and infection contexts. - Advanced Imaging and Biomarker Studies:
There is a growing interest in the use of advanced imaging techniques and biomarker identification to improve the diagnosis and management of thrombotic disorders.
Declining or Waning
- Traditional Diagnostic Assays:
There is a noticeable decrease in studies focused solely on traditional diagnostic assays for coagulation disorders, as newer, more advanced methodologies gain traction. - Basic Science Without Clinical Relevance:
Research that does not directly translate into clinical applications or patient outcomes appears to be receiving less attention, as the journal emphasizes studies with clear implications for patient care. - Pharmacological Interventions with Limited Evidence:
Topics that discuss pharmacological interventions lacking robust clinical trial data or clear efficacy are becoming less common, as the journal's readership seeks evidence-based findings. - Historical Perspectives:
Papers centered on historical analyses of thrombosis and hemostasis are decreasing, possibly as the focus shifts towards innovative and forward-looking research.
Similar Journals
HAEMOPHILIA
Empowering research for better patient outcomes.HAEMOPHILIA is a leading peer-reviewed journal published by Wiley, dedicated to advancing research and clinical practices in the fields of hematology and genetics. With an impressive Impact Factor and recognition within the Q1 category for Genetics (clinical), Hematology, and Medicine (miscellaneous), this journal presents a unique platform for the dissemination of high-quality research from 1995 to the present. Researchers in these dynamic fields will find invaluable insights through original articles, systematic reviews, and clinical trials, all aimed at improving therapeutic strategies and patient outcomes. Although it operates on a subscription basis, HAEMOPHILIA's commitment to excellence is reflected in its Scopus rankings, where it stands in the 74th percentile for hematology and the 71st percentile for clinical genetics. As an essential resource for academics, healthcare professionals, and students, HAEMOPHILIA plays a pivotal role in fostering innovation and collaboration within the global medical community.
Journal of Hematology & Oncology
Fostering Excellence in Hematology and Oncology ScholarshipJournal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.
BLOOD COAGULATION & FIBRINOLYSIS
Bridging Molecular Insights and Clinical ApplicationsBLOOD COAGULATION & FIBRINOLYSIS, a distinguished journal in the field of hematology, is published by Lippincott Williams & Wilkins, a reputable name in academic publishing. Since its inception in 1990, this journal has been committed to advancing the understanding of blood coagulation and fibrinolysis, focusing on the molecular mechanisms, clinical implications, and therapeutic aspects of these critical processes. With an impact factor reflecting its significance within the academic community, currently ranking Q3 in both Hematology and Miscellaneous Medicine for 2023, this journal serves as a pivotal platform for researchers and professionals alike. By providing access to cutting-edge research and reviews, BLOOD COAGULATION & FIBRINOLYSIS endeavors to foster collaboration and innovation in the treatment of coagulation disorders. Interested readers can explore ongoing contributions to the field through subscriptions and institutional access options.
BRITISH JOURNAL OF HAEMATOLOGY
Exploring Innovations in Blood Health and DiseaseBritish Journal of Haematology, published by Wiley, is a leading journal in the field of hematology, with an impressive impact factor reflecting its significance in the medical research community. Established in 1955, the journal has consistently contributed to advancing knowledge in hematology, currently holding a prestigious Q1 ranking in the Scopus category of Hematology, placing it in the top 18% of the field. The journal encompasses a broad range of topics including clinical and laboratory aspects of blood disorders and hematological malignancies, making it an essential resource for hematologists, researchers, and healthcare professionals. With its commitment to publishing top-tier research and clinical studies, the British Journal of Haematology plays a critical role in shaping treatment approaches and improving patient outcomes worldwide. Please note that this journal does not offer Open Access options, ensuring that published content is rigorously curated for quality and relevance.
Annals of Vascular Diseases
Illuminating the Pathways of Vascular ScienceAnnals of Vascular Diseases is a leading international journal dedicated to the comprehensive exploration of vascular pathology, aimed at advancing knowledge in the field through innovative research and insightful reviews. Published by the ANNALS VASCULAR DISEASES EDITORIAL OFFICE and available in both print (ISSN: 1881-641X) and electronic format (E-ISSN: 1881-6428), this journal has embraced Open Access since 2017, facilitating wider dissemination and accessibility of vital research findings. With its focus on clinical and experimental studies relating to vascular diseases, the journal serves as a crucial platform for researchers, medical professionals, and students who seek to stay at the forefront of clinical advancements. By fostering collaboration and sharing knowledge, Annals of Vascular Diseases plays a significant role in shaping the future of vascular research and treatment strategies worldwide.
BLOOD
Shaping the Future of Hematological Discovery.BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.
Lancet Haematology
Connecting researchers and clinicians for better patient outcomes.Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.
Journal of Atherosclerosis and Thrombosis
Innovating cardiovascular medicine through impactful research.Journal of Atherosclerosis and Thrombosis is a leading academic publication dedicated to advancing research in the fields of cardiovascular medicine, biochemistry, and internal medicine. Published by the Japan Atherosclerosis Society, this esteemed journal operates from its headquarters in Tokyo, Japan, and has been a vital resource in its area since its inception in 1994. With its robust impact in Cardiology and Cardiovascular Medicine, ranking in the top quartile (Q1) as of 2023, and a commendable standing in Internal Medicine and Biochemistry, the journal fosters an environment of innovation and discovery, showcasing significant studies and advancements that shape clinical practices and therapeutic approaches. Though not an open-access publication, it offers a wealth of insights to researchers, professionals, and students seeking to deepen their understanding of atherosclerosis and thrombosis. By continually featuring high-quality articles, the Journal of Atherosclerosis and Thrombosis plays an essential role in bridging the gap between research and practice, facilitating critical conversations that influence the future of cardiovascular health.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
Advancing knowledge in thrombosis and thrombolysis.JOURNAL OF THROMBOSIS AND THROMBOLYSIS, published by Springer in the Netherlands, serves as a vital platform for research in the fields of Cardiology and Cardiovascular Medicine and Hematology. With an impressive impact factor, this journal ranks in the Q2 category for both fields according to the latest metrics, evidencing its significant influence and contribution to ongoing scholarly discourse. Spanning over three decades from 1994 to 2024, the journal provides an essential source for innovative studies, clinical practices, and comprehensive reviews related to thrombosis and thrombolysis. Researchers, clinicians, and students alike will find valuable insights and cutting-edge knowledge that address the complexities of blood coagulation and its implications in cardiovascular health. The journal is indexed in Scopus, with commendable rankings, further establishing its reputation in the academic community.
CURRENT OPINION IN HEMATOLOGY
Bridging research and application in the realm of hematology.CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.